---
document_datetime: 2025-09-22 11:14:43
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/jayempi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: jayempi-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.9186334
conversion_datetime: 2025-12-28 13:24:59.22305
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Jayempi

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000257799 | Cardiac dysfunction (as part of hypersensitivity reactions) In view of | 24/07/2025                          | 17/09/2025                                  | SmPC and PL                      | Variation |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| available data on cardiac dysfunction (as part of hypersensitivity reactions) from the literature, including in seven cases a close temporal relationship, a positive de- challenge and/or re-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between azathioprine and cardiac dysfunction (as part of hypersensitivity reactions) is at least a reasonable possibility. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly. Cholestasis of pregnancy In view of available data on cholestasis of pregnancy from the literature, spontaneous reports including in eight cases a close temporal relationship and a positive de- challenge, and in view of a plausible mechanism of action, the PRAC considers a causal relationship between azathioprine and cholestasis of pregnancy is at least a reasonable possibility. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly. Pellagra / nicotinic acid deficiency In view of available data on pellagra from the literature, including 8 literature cases with a close temporal relationship and a positive de-challenge, and in view of a plausible mechanism of action, the PRAC considers a causal relationship   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

a reasonable possibility. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly.  Posterior reversible encephalopathy syndrome (PRES) In view of available data on posterior reversible encephalopathy syndrome from the literature, spontaneous reports including in some cases a close temporal relationship, a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between azathioprine and posterior reversible encephalopathy syndrome is at least a reasonable possibility. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly.  Sialoadenitis In view of available data on sialoadenitis from the literature, including 5 cases with a close temporal relationship, and a positive dechallenge and re-challenge, the PRAC considers a causal relationship between azathioprine and sialoadenitis is at least a reasonable possibility. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly.  Tremor In view of available data on tremor from the literature and spontaneous reports, including in some cases a close temporal relationship and a positive de-challenge and/or re-challenge,

<div style=\"page-break-after: always\"></div>

|                                          | the PRAC considers a causal relationship between azathioprine and tremor is at least a reasonable possibility. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly. Drug-drug interaction between azathioprine and allopurinol In view of available data on the interaction between azathioprine and allopurinol from spontaneous reports, the PRAC considers an amendment of the existing wording warranted. The PRAC concluded that the product information of products containing azathioprine should be amended accordingly.   |            |            |                        |                                                                                                                                                                                                                                                                  |
|------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000257074 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                                                                                                                                                                                       | 19/03/2025 | 17/09/2025 | SmPC, Labelling and PL | To update sections 4.4 and 4.8 of the SmPC and sections 2 and 4 of the PL to implement the signal recommendations on 'zathioprine - Non-cirrhotic portal hypertension / portosinusoidal vascular disease (EPITT no 20091)' adopted at the 28 November 2024 PRAC. |
| Variation type IA / EMA/VR/0000244745    | B.III.1.a European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph - B.III.1.a.2 Updated certificate from an already approved manufacturer - Accepted                                                                                                                                                                                                                                                                                                                                                                                                               | 14/01/2025 | N/A        |                        |                                                                                                                                                                                                                                                                  |